Peer-influenced content. Sources you trust. No registration required. This is HCN.

Clinical Oncology NewsStudy Provides New First-Line Standard for Advanced Bladder Cancer

Enfortumab Vedotin-ejfv Plus Pembrolizumab Sets New First-Line Standard

A groundbreaking international phase 3 study, EV302, has established a new first-line standard for advanced bladder cancer treatment. The study, presented at the 2023 annual congress of the European Society for Medical Oncology (ESMO), demonstrated that the combination of enfortumab vedotin-ejfv and pembrolizumab significantly outperforms chemotherapy.

Key Points

  • The median overall survival (OS) with enfortumab vedotin-ejfv plus pembrolizumab was 31.5 months, compared to 16.1 months with chemotherapy.
  • The risk of death was reduced by 53% compared to chemotherapy treatment.
  • Progression-free survival (PFS) was also significantly improved, with a median PFS of 12.5 months compared to 6.3 months with chemotherapy.
  • The superiority of enfortumab vedotin-ejfv plus pembrolizumab was consistent across subgroups, including cisplatin-eligible and -ineligible patients and patients with varying levels of PD-L1 expression.
  • Grade 3 and higher treatment-related adverse events (TRAEs) occurred in 56% of the enfortumab vedotin-ejfv plus pembrolizumab group and 70% of the chemotherapy group.

According to the American Cancer Society, about 83,730 new cases of bladder cancer will be diagnosed in the United States in 2023.

More on ESMO

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form